Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state …

Y Watanabe, I Tatsuno - Expert Review of Clinical Pharmacology, 2021 - Taylor & Francis
Introduction: An epidemiological study of Greenlandic Inuit suggested the importance of
omega-3 polyunsaturated fatty acids (PUFAs) in preventing ischemic heart disease. After …

Do omega-3 polyunsaturated fatty acids prevent cardiovascular disease? A review of the randomized clinical trials

LM Kimmig, DG Karalis - Lipid Insights, 2013 - journals.sagepub.com
Fish oil is rich in the omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA). Numerous epidemiological studies and several …

Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials

B Yang, PT Tseng, X Hu, BY Zeng, JPC Chang… - Progress in Lipid …, 2022 - Elsevier
The role of omega-3 polyunsaturated fatty acids (PUFAs) in primary and secondary
prevention on major cardiovascular events (MCE) is inconclusive due to the potential …

Omega-3 polyunsaturated fatty acids and cardiovascular diseases

CJ Lavie, RV Milani, MR Mehra, HO Ventura - Journal of the American …, 2009 - jacc.org
Omega-3 polyunsaturated fatty acid (ω-3 PUFA) therapy continues to show great promise in
primary and, particularly in secondary prevention of cardiovascular (CV) diseases. The most …

Omega-3 fatty acids and cardiovascular disease: are there benefits?

KJ Bowen, WS Harris, PM Kris-Etherton - Current treatment options in …, 2016 - Springer
Opinion statement Early secondary prevention trials of fish and omega-3 polyunsaturated
fatty acid (PUFA) capsules reported beneficial effects on cardiovascular disease (CVD) …

Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated …

M Casula, E Olmastroni, M Gazzotti, F Galimberti… - Pharmacological …, 2020 - Elsevier
The recent publication of the REDUCE-IT study has reopened the debate about the efficacy
of omega-3 fatty acids in reducing the risk of cardiovascular (CV) events. This meta-analysis …

Statin Use Mitigate the Benefit of Omega-3 Fatty Acids Supplementation—A Meta-Regression of Randomized Trials

A Sethi, A Bajaj, S Khosla, RR Arora - American Journal of …, 2016 - journals.lww.com
During last 2 decades, multiple studies have evaluated omega-3 polyunsaturated fatty acids
(ω-3 PUFA) supplementation for cardiovascular prevention. The benefit found in previous …

Omega-3 fatty acids in arterial hypertension: iS there any good news?

G Brosolo, A Da Porto, S Marcante, A Picci… - International journal of …, 2023 - mdpi.com
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), including alpha-linolenic acid (ALA) and
its derivatives eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are …

Dose-dependent risk reduction for myocardial infarction with eicosapentaenoic acid: a meta-analysis and meta-regression including the STRENGTH trial

P Sarajlic, G Artiach, SC Larsson, M Bäck - Cardiovascular Drugs and …, 2021 - Springer
Numerous trials have investigated the role of the long-chain omega-3 polyunsaturated fatty
acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the …

Pros and cons of long-chain omega-3 polyunsaturated fatty acids in cardiovascular health

I Djuricic, PC Calder - Annual review of pharmacology and …, 2023 - annualreviews.org
The long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), are found in seafood, supplements, and concentrated pharmaceutical …